Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $26.0 million.

  • Cartesian Therapeutics' Shares Outstanding (Weighted Average) rose 2110.47% to $26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year increase of 2110.47%. This contributed to the annual value of $17.3 million for FY2024, which is 23415.39% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Shares Outstanding (Weighted Average) stood at $26.0 million, which was up 2110.47% from $26.0 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Shares Outstanding (Weighted Average) registered a high of $152.8 million during Q3 2022, and its lowest value of $5.1 million during Q1 2023.
  • Over the past 5 years, Cartesian Therapeutics' median Shares Outstanding (Weighted Average) value was $26.0 million (recorded in 2025), while the average stood at $62.3 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Shares Outstanding (Weighted Average) tumbled by 9662.4% in 2023, and later surged by 37843.65% in 2025.
  • Over the past 5 years, Cartesian Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $114.3 million in 2021, then grew by 26.62% to $144.8 million in 2022, then plummeted by 96.43% to $5.2 million in 2023, then soared by 234.15% to $17.3 million in 2024, then soared by 50.51% to $26.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $26.0 million for Q3 2025, versus $26.0 million for Q2 2025 and $25.9 million for Q1 2025.